Iovance Biotherapeutics Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation

Reuters11-06

<a href="https://laohu8.com/S/IOVA">Iovance Biotherapeutics</a> Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation

Iovance Biotherapeutics Inc. released a corporate presentation highlighting its leadership in the development and commercialization of tumor infiltrating lymphocyte $(TIL)$ therapies for cancer patients. The company reported that more than 1,000 commercial and clinical patients have been treated with its TIL products, including Amtagvi, which has received approval in the U.S. and Canada. Iovance disclosed prior 12-month product revenue of approximately $250 million and a workforce of about 1,000 employees. The presentation detailed a global advanced melanoma patient treatment opportunity exceeding 70,000 individuals and noted regulatory filings under review in the UK and Australia. Iovance's pipeline includes registrational programs in melanoma and non-small cell lung cancer, as well as next-generation TIL products and ongoing clinical trials. The company reported a cash position of roughly $307 million as of the end of the third quarter of 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581990460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581990460","market":"us","top_or_hot":-1,"title":"Iovance Biotherapeutics Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iovance Biotherapeutics Inc. released a corporate presentation highlighting its leadership in the development and commercialization of tumor infiltrating lymphocyte <a href=\"https://laohu8.com/S/TIL\">$(TIL)$</a> therapies for cancer patients. The company reported that more than 1,000 commercial and clinical patients have been treated with its TIL products, including Amtagvi, which has received approval in the U.S. and Canada. Iovance disclosed prior 12-month product revenue of approximately $250 million and a workforce of about 1,000 employees. The presentation detailed a global advanced melanoma patient treatment opportunity exceeding 70,000 individuals and noted regulatory filings under review in the UK and Australia. Iovance's pipeline includes registrational programs in melanoma and non-small cell lung cancer, as well as next-generation TIL products and ongoing clinical trials. The company reported a cash position of roughly $307 million as of the end of the third quarter of 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iovance Biotherapeutics Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIovance Biotherapeutics Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 22:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/IOVA\">Iovance Biotherapeutics</a> Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Iovance Biotherapeutics Inc. released a corporate presentation highlighting its leadership in the development and commercialization of tumor infiltrating lymphocyte <a href=\"https://laohu8.com/S/TIL\">$(TIL)$</a> therapies for cancer patients. The company reported that more than 1,000 commercial and clinical patients have been treated with its TIL products, including Amtagvi, which has received approval in the U.S. and Canada. Iovance disclosed prior 12-month product revenue of approximately $250 million and a workforce of about 1,000 employees. The presentation detailed a global advanced melanoma patient treatment opportunity exceeding 70,000 individuals and noted regulatory filings under review in the UK and Australia. Iovance's pipeline includes registrational programs in melanoma and non-small cell lung cancer, as well as next-generation TIL products and ongoing clinical trials. The company reported a cash position of roughly $307 million as of the end of the third quarter of 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLnZxnL:1","article_id":"2581990460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581990460","pubTimestamp":1762438150,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Iovance Biotherapeutics Inc. released a corporate presentation highlighting its leadership in the development and commercialization of tumor infiltrating lymphocyte  therapies for cancer patients. The company reported that more than 1,000 commercial and clinical patients have been treated with its TIL products, including Amtagvi, which has received approval in the U.S. and Canada. Iovance disclosed prior 12-month product revenue of approximately $250 million and a workforce of about 1,000 employees. The presentation detailed a global advanced melanoma patient treatment opportunity exceeding 70,000 individuals and noted regulatory filings under review in the UK and Australia. Iovance's pipeline includes registrational programs in melanoma and non-small cell lung cancer, as well as next-generation TIL products and ongoing clinical trials. The company reported a cash position of roughly $307 million as of the end of the third quarter of 2025. You can access the full presentation through t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Iovance Biotherapeutics在新的公司演示中展示了TIL疗法的进展和产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":0.9},"content_text":"Iovance Biotherapeutics Showcases TIL Therapy Advances and Pipeline in New Corporate Presentation\n    \n\n        Iovance Biotherapeutics Inc. released a corporate presentation highlighting its leadership in the development and commercialization of tumor infiltrating lymphocyte $(TIL)$ therapies for cancer patients. The company reported that more than 1,000 commercial and clinical patients have been treated with its TIL products, including Amtagvi, which has received approval in the U.S. and Canada. Iovance disclosed prior 12-month product revenue of approximately $250 million and a workforce of about 1,000 employees. The presentation detailed a global advanced melanoma patient treatment opportunity exceeding 70,000 individuals and noted regulatory filings under review in the UK and Australia. Iovance's pipeline includes registrational programs in melanoma and non-small cell lung cancer, as well as next-generation TIL products and ongoing clinical trials. The company reported a cash position of roughly $307 million as of the end of the third quarter of 2025. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581990460","isCrawlerRequest":true}